| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | 0 |
Sells | $124,529 | 21 | 100 |
| Foody Joanne M. | Chief Medical Officer | 0 | $0 | 2 | $11,801 | $-11,801 |
| Halladay Benjamin | Chief Financial Officer | 0 | $0 | 5 | $13,157 | $-13,157 |
| Warren Eric | Chief Commercial Officer | 0 | $0 | 11 | $23,122 | $-23,122 |
| Koenig Sheldon L. | President and CEO | 0 | $0 | 3 | $76,449 | $-76,449 |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Over the last 12 months, insiders at Esperion Therapeutics, Inc. have bought $0 and sold $124,529 worth of Esperion Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Esperion Therapeutics, Inc. have bought $5.33M and sold $91,848 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 23,091 shares for transaction amount of $36,285 was made by CARROLL J MARTIN (director) on 2023‑05‑11.
| 2025-04-17 | Sale | Halladay Benjamin | Chief Financial Officer | 8 <0.0001% | $0.96 | $8 | -4.49% | |
| 2025-04-17 | Sale | Warren Eric | Chief Commercial Officer | 108 <0.0001% | $0.98 | $106 | -4.49% | |
| 2025-03-18 | Sale | Koenig Sheldon L. | President and CEO | 13,047 0.0063% | $1.50 | $19,623 | -36.98% | |
| 2025-03-18 | Sale | Halladay Benjamin | Chief Financial Officer | 3,535 0.0017% | $1.48 | $5,242 | -36.98% | |
| 2025-03-18 | Sale | Warren Eric | Chief Commercial Officer | 2,433 0.0012% | $1.49 | $3,618 | -36.98% | |
| 2025-02-19 | Sale | Halladay Benjamin | Chief Financial Officer | 11 <0.0001% | $1.86 | $20 | -41.45% | |
| 2025-02-19 | Sale | Warren Eric | Chief Commercial Officer | 239 0.0001% | $1.87 | $446 | -41.45% | |
| 2025-01-17 | Sale | Halladay Benjamin | Chief Financial Officer | 9 <0.0001% | $2.27 | $20 | -37.10% | |
| 2025-01-17 | Sale | Warren Eric | Chief Commercial Officer | 123 <0.0001% | $2.26 | $278 | -37.10% | |
| 2024-12-17 | Sale | Koenig Sheldon L. | President and CEO | 12,447 0.0064% | $2.47 | $30,694 | -35.77% | |
| 2024-12-17 | Sale | Halladay Benjamin | Chief Financial Officer | 3,245 0.0016% | $2.42 | $7,866 | -35.77% | |
| 2024-12-17 | Sale | Warren Eric | Chief Commercial Officer | 2,234 0.0011% | $2.43 | $5,426 | -35.77% | |
| 2024-11-19 | Sale | Warren Eric | Chief Commercial Officer | 197 <0.0001% | $2.17 | $427 | -30.50% | |
| 2024-10-17 | Sale | Warren Eric | Chief Commercial Officer | 107 <0.0001% | $2.12 | $227 | -13.74% | |
| 2024-09-17 | Sale | Koenig Sheldon L. | President and CEO | 14,550 0.0075% | $1.80 | $26,132 | +2.25% | |
| 2024-09-17 | Sale | Warren Eric | Chief Commercial Officer | 2,608 0.0013% | $1.78 | $4,650 | +2.25% | |
| 2024-08-19 | Sale | Warren Eric | Chief Commercial Officer | 211 0.0001% | $1.95 | $411 | -6.32% | |
| 2024-07-17 | Sale | Foody Joanne M. | Chief Medical Officer | 917 0.0005% | $2.60 | $2,383 | -29.96% | |
| 2024-07-17 | Sale | Warren Eric | Chief Commercial Officer | 108 <0.0001% | $2.59 | $279 | -29.96% | |
| 2024-06-18 | Sale | Foody Joanne M. | Chief Medical Officer | 3,285 0.0019% | $2.87 | $9,418 | -30.88% |
| Koenig Sheldon L. | President and CEO | 1571962 0.7931% | $1.84M | 2 | 8 | +11.27% |
| Halladay Benjamin | Chief Financial Officer | 481702 0.243% | $563,591.34 | 0 | 5 | |
| Warren Eric | Chief Commercial Officer | 370218 0.1868% | $433,155.06 | 1 | 26 | |
| Foody Joanne M. | Chief Medical Officer | 272862 0.1377% | $319,248.54 | 0 | 8 | |
| BIOTECH TARGET N V | 10 percent owner | 4477964 2.2593% | $5.24M | 21 | 0 | <0.0001% |
| DOMAIN PARTERS VII L P | 10 percent owner | 2566935 1.2951% | $3M | 2 | 0 | +89.57% |
| Alta Partners VIII, L.P. | 10 percent owner | 2552189 1.2877% | $2.99M | 2 | 0 | +89.57% |
| TREU JESSE I | 10 percent owner | 2066935 1.0429% | $2.42M | 1 | 0 | +8.67% |
| BLAIR JAMES C | 10 percent owner | 2066935 1.0429% | $2.42M | 1 | 0 | +8.67% |
| DOVEY BRIAN H | 10 percent owner | 2066935 1.0429% | $2.42M | 1 | 0 | +8.67% |
| SCHOEMAKER KATHLEEN K | 10 percent owner | 2066935 1.0429% | $2.42M | 1 | 0 | +8.67% |
| Halak Brian K | 10 percent owner | 2066935 1.0429% | $2.42M | 1 | 0 | +8.67% |
| Aisling Capital II LP | 10 percent owner | 1837125 0.9269% | $2.15M | 1 | 2 | +8.67% |
| JANNEY DANIEL | director | 1359967 0.6862% | $1.59M | 2 | 1 | +89.57% |
| Boxer Capital, LLC | 10 percent owner | 1101250 0.5556% | $1.29M | 0 | 2 | |
| GOLDSTEIN DOV A MD | director | 837125 0.4224% | $979,436.25 | 1 | 4 | +8.67% |
| NEWTON ROGER S | director | 548726 0.2769% | $642,009.42 | 1 | 9 | +8.67% |
| LANGE LOUIS G | director | 197703 0.0997% | $231,312.51 | 1 | 0 | +8.67% |
| MAYLEBEN TIMOTHY M | President & CEO | 111998 0.0565% | $131,037.66 | 14 | 0 | <0.0001% |
| Looker Benjamin | General Counsel | 83663 0.0422% | $97,885.71 | 0 | 2 | |
| CARROLL J MARTIN | director | 36500 0.0184% | $42,705.00 | 3 | 0 | +7.64% |
| DP VII ASSOCIATES LP | 10 percent owner | 35253 0.0178% | $41,246.01 | 1 | 0 | +8.67% |
| Longitude Capital Partners, LLC | 10 percent owner | 28186 0.0142% | $32,977.62 | 1 | 4 | +8.67% |
| ENRIGHT PATRICK G | director | 18361 0.0093% | $21,482.37 | 1 | 5 | +8.67% |
| Bartram Richard | Chief Financial Officer | 11092 0.0056% | $12,977.64 | 0 | 1 | |
| ROCAMBOLI STEPHEN | director | 8111 0.0041% | $9,489.87 | 1 | 0 | +8.56% |
| MCGOVERN MARK E | director | 5000 0.0025% | $5,850.00 | 2 | 0 | +31.56% |
| Lalwani Narendra D. | Chief Operating Officer | 5000 0.0025% | $5,850.00 | 1 | 0 | +251.57% |
| OMENN GILBERT S | director | 1000 0.0005% | $1,170.00 | 3 | 0 | +59.71% |
| VITULLO NICOLE | director | 0 0% | $0 | 1 | 3 | +8.67% |
$2,051,022 | 1591 | -12.84% | $78.4M | |
$22,899,264 | 81 | 34.90% | $19.09M | |
Esperion Therapeutics, Inc. (ESPR) | $218,350,131 | 64 | 16.68% | $231.89M |
$129,489,279 | 57 | 26.09% | $389.44M | |
$125,860,243 | 57 | -4.48% | $32.12M | |
$2,740,482 | 50 | 9.37% | $31.51M | |
$33,884,330 | 45 | 12.58% | $454.37M | |
$97,642,477 | 41 | -10.58% | $640.24M | |
$6,021,989 | 30 | -0.17% | $339.7M | |
$423,174,478 | 29 | -7.58% | $27.75M | |
$17,389,773 | 25 | -6.03% | $292.86M | |
$25,034,841 | 20 | 9.38% | $100.33M | |
$758,061 | 9 | 60.03% | $157.72M | |
$1,683,154 | 8 | 46.59% | $414.31M | |
$179,515 | 7 | 1.51% | $339.24M | |
$543,932 | 6 | -22.03% | $558.71M | |
$103,523 | 3 | 9.40% | $60.52M | |
$5,003,136 | 1 | -14.58% | $249.18M | |
$999,999 | 1 | -52.42% | $16.76M |
| Increased Positions | 82 | +37.1% | 15M | +11.99% |
| Decreased Positions | 86 | -38.91% | 24M | -18.82% |
| New Positions | 26 | New | 9M | New |
| Sold Out Positions | 30 | Sold Out | 4M | Sold Out |
| Total Postitions | 217 | -1.81% | 120M | -6.83% |
| Wasatch Advisors Lp | $26,686.00 | 12.37% | 24.48M | +1M | +4.87% | 2024-12-31 |
| Blackrock, Inc. | $15,797.00 | 7.32% | 14.49M | +257,597 | +1.81% | 2025-03-31 |
| Vanguard Group Inc | $12,770.00 | 5.92% | 11.72M | -1M | -10.18% | 2024-12-31 |
| Bellevue Group Ag | $10,839.00 | 5.02% | 9.94M | 0 | 0% | 2024-12-31 |
| Morgan Stanley | $6,877.00 | 3.19% | 6.31M | +4M | +138.43% | 2024-12-31 |
| Two Seas Capital Lp | $6,792.00 | 3.15% | 6.23M | -353,407 | -5.37% | 2024-12-31 |
| State Street Corp | $4,910.00 | 2.28% | 4.5M | +649,920 | +16.86% | 2024-12-31 |
| Geode Capital Management, Llc | $4,731.00 | 2.19% | 4.34M | +8,634 | +0.2% | 2024-12-31 |
| Meditor Group Ltd | $4,133.00 | 1.92% | 3.79M | 0 | 0% | 2024-09-30 |
| Two Sigma Advisers, Lp | $3,942.00 | 1.83% | 3.62M | +16,100 | +0.45% | 2024-12-31 |